Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Nonprofit Harm Reduction Therapeutics targets an OTC switch of naloxone, an opioid antagonist used to reverse an opioid overdose. It aims to make the product available at low cost in 110,000 retail locations nationwide.
Latest From Consumer
An FDA final rule rejects generally regarded as safe and effective status for 24 OTC monograph antiseptic ingredients regarding products intended for use by health care professionals in hospitals or similar venues. However, six ingredients on which FDA deferred its decision also are used in consumer antiseptic washes, which GRASE decisions pending in separate rulemakings.
FDA seeks broader guidance than comments and information submitted at a January public hearing on standards testing and evaluations that could expand the variety of products approved as NRTs The docket is open to "recommend specific topics for direct, collective engagement and consideration by the" steering committee.
Review was second in two years by the Council of Better Business Bureaus' National Advertising Division of a challenge to Reckitt Benckiser ad claims for its Mucinex cough/cold line made by Procter & Gamble, which markets competing products including Vicks NyQuil and DayQuil brands.
P&G says harmful plaque bacteria below the gum line evades "even the most the diligent brushers." The firm plans in 2020 to move manufacturing of hair, oral and personal care products from Iowa to a facility in West Virginia.
Firm says it also looks to grow WaterPik sales with investment in international channels. Water Pik subsidiary says Whitening Water Flosser mixes a whitening agent with water, using its proprietary Whitening Infuser technology, and is sold with a 30-day supply of whitening tablets.
Firm's "power brands" in respiratory and pain areas achieved high single-digit sales growth in the fourth quarter on an “earlier and more severe” cold season that also drove overall consumer health sales in the period up 4.3% to $2.65bn.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.